BioSpace News Archive

Visiopharm, the leader in precision pathology software, and Proscia, a leader in digital pathology image and workflow management, have entered into a multi-year, strategic partnership to deliver deeply integrated AI-enabled solutions that drive breakthroughs in translational research and advance precision medicine

McKesson Corporation (NYSE:MCK) today announced that its previously announced offer to stockholders to exchange their shares of McKesson common stock on a per-share-basis for 11.4086 shares of PF2 SpinCo, Inc. (“SpinCo”) common stock expired at 11:59 p.m., New York City time, on March 9, 2020, and, based on preliminary results, the exchange offer was oversubscribed.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings with the U.S. Food and Drug Administration (FDA) for INOpulse ® for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). The Company, in consultation with the FDA, has finalized the key elements of its planned pivotal Ph

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it achieved key milestones in an early development program in corn to evaluate novel seed yield traits.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DARE-BV1 for the treatment of bacterial vaginosis (BV) in women. DARE-BV1 was previously granted Qualified Infectious Disease Product (QIDP) designation for the treatment of BV in August 2019.

InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth quarter and year ended December 31, 2019.

Catalyst Pharmaceuticals, Inc. announced that it will release fourth quarter and year end 2019 financial results after market close on Monday, March 16, 2020.

InCrowd, the pioneer of real-time, high-quality, primary market intelligence for the life science industry, has appointed Joseph Baldini to lead its engineering function as InCrowd continues to broaden its technological capabilities and grow the market for mobile-first, on-demand market insights.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2019 financial results before the market opens on Thursday, March 19, 2020.

Varian announced Medisch Spectrum Twente Hospital in The Netherlands, and Icon Cancer Centre Wahroonga and Royal North Shore Hospital in Australia treated their first patients with Ethos™ therapy.